Roche reports Phase 2 enicepatide data in overweight or obese patients with diabetes

Roche is back with more data Tuesday for the lead drug it obtained from Carmot Therapeutics — this time from a mid-stage trial in overweight or obese people with type 2 diabetes. The Swiss drugmaker’s enicepatide ...